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Abstract
 
To gain insights into the mechanisms by which soluble heat shock protein (hsp) fusions can
elicit CD8
 
1
 
 cytotoxic T lymphocytes (CTLs) against the fusion partner, mycobacterial (
 
Myco-
bacterium tuberculosis
 
) hsp70 was dissected to ascertain whether a particular hsp domain is neces-
sary, and knockout mice were used to determine whether the fusion protein’s immunogenicity
is dependent on CD4
 
1
 
 T lymphocytes. We found that the ability to elicit CD8
 
1
 
 CTLs depends
on a discrete 200–amino acid protein domain, indicating that the fusion protein’s immunoge-
nicity for CD8
 
1
 
 T cells does not require coupled chaperone function or peptide binding. Fur-
ther, we found that ovalbumin (OVA).hsp70 fusion protein elicited anti-OVA CD8
 
1
 
 CTLs
about equally well in CD4 knockout and wild-type C57BL/6 mice, and also when the hsp70
was of murine (self) origin. The ability of hsp70 fusion proteins to elicit CD4-independent
CTL responses suggests that hsp70 fusion proteins may be useful for immunological prophylaxis
and therapy against disease in CD4
 
1
 
 T cell–deficient individuals.
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Introduction
 
There is now substantial evidence that heat shock proteins
(hsps) isolated from tumors can be used as adjuvant-free anti-
tumor vaccines in animals; hsp70 and the distantly related
chaperones gp96 and calreticulin share this immunostim-
ulatory activity (1–6). The fusion of large polypeptides
(80–110 amino acids [aa] in length) to mycobacterial hsp70
(TBhsp70) creates potent immunogens that can elicit MHC
class I–restricted, CD8
 
1
 
 CTL responses sufficient to mediate
rejection of tumors expressing the fusion partner (7). The
need for more effective immunological prophylaxis and
therapy for cancer and infectious diseases caused by intracel-
lular pathogens has spurred intense investigation of immuno-
gens and immunization strategies aimed at eliciting effective
CD8
 
1
 
 CTL responses. For example, CTL epitopes have
been expressed in the context of Ty virus–like particles, or
tailed with lipids (8). Antigenic peptides have been fused to
toxins (9–11), cytokines (12, 13), and proteins that cross cell
membranes, such as HIV-1 Tat (14), and hsp70 (7).
The means by which soluble hsp70 fusion proteins stim-
ulate CD8
 
1
 
 CTL responses are unknown. Among the pos-
sible mechanisms are (a) strong hsp-specific CD4
 
1
 
 helper
cell responses that enhance what might otherwise be a min-
imal response to the soluble proteins (15–18), and (b) the
chaperone function of hsps that delivers the fusion protein
to intracellular compartments of APCs for processing into
short peptides and loading onto MHC class I (19, 20). We
demonstrate here that hsp70 fusion proteins can elicit
CD8
 
1
 
 CTLs in the absence of CD4
 
1
 
 T lymphocytes and
that this function resides in a 200-aa segment of TBhsp70,
indicating that chaperone activity is not required.
 
Materials and Methods
 
Expression Vectors.
 
All constructs used to produce OVA.hsp70
fusion proteins were made in the bacterial expression plasmid
pKS11h (7). Fusion constructs, consisting of OVA fused to the
NH
 
2
 
 terminus of various segments of hsp70, were inserted down-
stream of the histidine tag sequence. A portion of OVA (aa 230–
359) was amplified from pOV230 (21) by PCR using upstream
primer oQH025 and the downstream primer oQH027 (the se-
quences of these and other PCR primers are listed at the end of
Materials and Methods). The OVA expression vector pQH07
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was constructed by subcloning OVA into the NdeI and NheI
sites of pKS11h. Full-length TBhsp70 and four truncated TBhsp70
segments I (aa 1–166), II (aa 161–370), III (aa 360–517), and IV
(aa 510–625), were amplified from plasmid pY3111/8 (gift of W.
Wu, StressGen Biotechnologies, Victoria, Canada). The up-
stream primer for the full-length TBhsp70 and segment I is
oQH001, and the downstream primers are oJR061 and oQH011,
respectively. The upstream primers for TBhsp70 II, III, and IV
are oQH012, oQH014, and oQH016, respectively; the down-
stream primers are oQH013, oQH015, and oJR061, respectively.
The plasmids pQH06, pQH08, pQH09, pQH10, and pQH11,
which express OVA fused to TBhsp70, TBhsp70 I, II, III, and IV,
respectively, were constructed by subcloning the full-length and
truncated TBhsp70 PCR products into the BamHI and EcoRI
sites of pQH07 (at the COOH terminus of OVA). Murine
hsp70.1 coding sequence (mhsp70) was amplified from plasmid
pmhsp70.1 by PCR using the upstream primer oJR102 and the
downstream primer oJR103. Plasmid pQH12, expressing OVA.
mhsp70 fusion protein, was created by subcloning mhsp70 into
the BamHI and EcoRI sites of pQH07. All plasmids were veri-
fied by sequencing in both directions with double-stranded DNA
templates.
 
Recombinant Protein Purification.
 
OVA, OVA.TBhsp70, OVA.
TBhsp70 II, OVA.TBhsp70 III, and OVA.TBhsp70 IV were in-
duced in 
 
Escherichia coli
 
 (BL21[DE3]pLysS) for 9 h at 25
 
8
 
C in the
presence of 0.5–1 mM isopropyl thiogalactoside (IPTG), and were
purified as soluble proteins. The mycobacterial segment I and
murine hsp70 fusion proteins were induced in 
 
E. coli
 
 for 4 h at
37
 
8
 
C with 1 mM IPTG, purified from inclusion bodies, and then
refolded as described previously (7, 16). All proteins were puri-
fied using nitrilo-triacetic acid Ni
 
1
 
 column (Qiagen) and Hi-
Trap
 
®
 
 Q anion exchange chromatography (Amersham Pharmacia
Biotech), as described previously (7, 16). Purity was assessed us-
ing 4–20% gradient SDS-PAGE gels stained with Coomassie blue
(Bio-Rad). All proteins were dialyzed against PBS and sterile fil-
tered at 0.2 
 
m
 
M. Protein concentrations were measured by Lowry
assay (Bio-Rad) and expressed in molar terms to allow simple
comparison of proteins of differing molecular weights.
 
Mice and Immunizations.
 
6–8-wk-old female C57BL/6, CD4
 
2
 
/
 
2
 
,
and 
 
b
 
2-microglobulin (
 
b
 
2m)
 
2
 
/
 
2
 
 mice were obtained from The
Jackson Laboratory and Taconic Farms. Both knockout mice
have C57BL/6 (H-2
 
b
 
) genetic backgrounds. Groups of three or
four mice were injected intraperitoneally with 120 pmol of re-
combinant protein in PBS; a second injection was performed
subcutaneously 2 wk later. The mice were killed 10 d after the
boost, and splenocytes within groups were pooled (7).
 
Cell Line.
 
EG7-OVA cells were cultured as described previ-
ously (7).
 
CTL Assays.
 
CTL assays were performed as described (7).
Results shown are representative of experiments repeated two to
five times.
The PCR primer sequences were as follows: for oQH025,
5
 
9
 
-GCAGTACTCATATGATCCTGGAGCTTCCATTTGCC-
AGTGGGACAATG-3
 
9
 
; for oQH027, 5
 
9
 
-CTCCGACCTCAC-
CTACGACGTTCGCAGAGACTTCTTAAAATTATCCGATG-
CTAGACCTAGT-3
 
9
 
; for oQH001, 5
 
9
 
-ATAGTACTGGATC-
CATGGCTCGTGCGGTCGGGATCGACCTCGGG-3
 
9
 
; for
oJR061, 5
 
9
 
-GGAATTCCTATCTAGTCACTTGCCCTCCCG-
GCCGTC-3
 
9
 
; for oQH011, 5
 
9
 
-GTCGACGAATTCATCATCA-
GATCGCGCTCTTCTCGCCCTTGTCGAG-3
 
9
 
; for oQH012,
5
 
9
 
-GTCGACGGATCCATGGAGAAGGAGCAGCGAATCCT-
GGTCTTCGACTTG-3
 
9
 
; for oQH014, 5
 
9
 
-GTCGACGGATCCA-
TGGTGAAAGACGTTCTGCTGCTTGATGTTACCCCG-3
 
9
 
;
 
for oQH016, 5
 
9
 
-GTCGACGGATCCATGCGTAATCAAGC-
CGAGACATTGGTCTACCAGACG-3
 
9
 
; for oQH013, 5
 
9
 
-GTC-
GACGAATTCATCACGGGGTAACATCAAGCAGCAGAAC-
GTCTTTCAC-3
 
9
 
; for oQH015, 5
 
9
 
-GTCGACGAATTCATCA-
GACCAATGTCTCGGCTTGATTACGAACATCGGC-3
 
9
 
; for
oJR102, 5
 
9
 
-TCTAGAGGATCCATGGCCAAGAACACGGC-
GATC-3
 
9
 
; and for oJR103, 5
 
9
 
-TCTAGAGAATTCCTAATC-
CACCTCCTCGATGGTGGGTCC-3
 
9
 
.
 
Results and Discussion
 
Our previous studies demonstrated that soluble, adjuvant-
free TBhsp70 fusion proteins elicit substantial immune re-
sponses, including CD8
 
1
 
 CTLs, in mice (7, 16). The basis
for the effectiveness of hsp70 fusions is unclear, as most sol-
uble proteins do not elicit significant CD8
 
1
 
 T cell responses
(for reviews, see references 22 and 23).
 
 
 
Although there is
evidence that the
 
 
 
hsp moiety of TBhsp fusion proteins acts
as an effective carrier in the classic sense, enhancing B cell
responses to chemically conjugated pneumococcal polysac-
charides (18) and malarial polypeptide (15), carriers are not
known to stimulate CTL production.
 
 
 
We thought
 
 
 
it more
likely that hsp70 fusion proteins provide hsp70-specific
cognate CD4
 
1
 
 T cell help to OVA-specific CD8
 
1
 
 CTLs
by activating shared professional APCs, as suggested by
many and demonstrated recently (24–26).
We tested this cognate help hypothesis using CD4-defi-
cient (knockout) mice (CD4
 
2
 
/
 
2
 
). Wild-type C57BL/6,
CD4
 
2
 
/
 
2
 
, and 
 
b
 
2m
 
2
 
/
 
2
 
 mice were each immunized with
OVA or OVA.TBhsp70 fusion protein. As expected, im-
munization of wild-type mice with OVA.TBhsp70, but
not OVA, generated CTLs specific for the immunodomi-
nant epitope of OVA (SIINFEKL; Fig. 1 A). The same re-
sults were obtained when the CD4
 
2
 
/
 
2
 
 mice were immu-
nized with OVA.TBhsp70 (Fig. 1 B). 
 
b
 
2m
 
2
 
/
 
2
 
 mice, which
have very few CD8
 
1
 
 T cells, did not develop OVA-spe-
cific CTLs after immunization with OVA.TBhsp70 or with
OVA alone (Fig. 1 C).
Previous efforts to determine whether CD4
 
1
 
 T cell help
is necessary for generation of CD8
 
1
 
 CTLs have drawn dif-
fering conclusions. CD4 knockout mice exhibit a range of
CD8
 
1
 
 CTL responses: CD4-dependent, weakly dependent,
or independent. CTL responses to minor histocompatibil-
ity antigens (25, 27) or to OVA loaded into spleen cells
(28)
 
 
 
are CD4 dependent.
 
 
 
Some potent CD8
 
1
 
 T cell im-
munogens, including viruses (29)
 
 
 
such as lymphocytic
choriomeningitis virus (30–33),
 
 
 
ectromelia virus (34), and
some influenza virus subtypes (35), as well as allogeneic
cells (36), elicit strong CD8
 
1
 
 T cell responses in wild-type
and CD4
 
2
 
/
 
2
 
 mice.
 
 
 
The CD4 independence of the CTL
response seen in Fig. 1 B does not exclude some role for
CD4
 
1
 
 help in normal mice immunized with hsp70 fusion
proteins. Although it is possible that CD4
 
2
 
/CD8
 
2
 
 double-
negative T cells provide weak residual help in CD4
 
2
 
/
 
2
 
mice, it is unlikely that such weak help is responsible for
the anti-OVA CTLs seen in Fig. 1 B. The similarity of CD8
 
1
 
CTL responses to OVA.TBhsp70 in CD4
 
2
 
/
 
2
 
 and wild-
type mice suggests that hsp70 fusion proteins are relatively 
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potent CD8
 
1
 
 CTL immunogens. A similar result, showing
that CD4
 
1
 
 T cells are not required for the CD8
 
1
 
 CTL re-
sponse elicited by another mycobacterial heat shock fusion
protein (hsp65 fused to a polypeptide containing an epitope
for 2C CD8
 
1
 
 T cells), has also been obtained using CD4
 
2
 
/2
mice (Cho, B., personal communication). In addition,
the ability of a nonhomologous hsp, gp96, to elicit tumor
rejection requires CD41 T cells at tumor challenge, but not
during priming with tumor-derived gp96 (2).
It has been proposed that the immunostimulatory effects
of certain hsp fusion proteins may be due to the bacterial or-
igin of the hsp moiety (20). We examined this possibility by
making OVA.hsp70 fusion proteins with the murine homo-
logue of TBhsp70 (37), here referred to as mhsp70. Immuni-
zation of wild-type C57BL/6 mice with OVA.mhsp70, but
not OVA, elicited CTL responses equivalent to those gen-
erated by the TBhsp70 fusion protein (Fig. 2 A). The re-
sponse to OVA.mhsp70 was also independent of CD4 (Fig.
2 B). Since a CD41 T cell response to self (murine) hsp70
is unlikely, the effectiveness of the murine hsp70 fusion
protein is in accord with the more direct evidence for CD4
independence obtained using CD42/2 mice (see above).
The ability of hsp fusion proteins to elicit CTLs against
the fusion partner may be a consequence of the hsp moi-
eties’ chaperone activity, assuming that this activity is pre-
served in the fusion protein. To investigate this issue, we
divided TBhsp70 into four linear segments and fused
OVA to the NH2 terminus of each segment, creating
OVA.TBhsp70s I–IV (Fig. 3 A). Each segment corresponds
to a distinct structural domain of hsp70, as described by
Flaherty et al. (38) and Zhu et al. (39). As shown in Fig. 3 A,
the NH2-terminal ATP-binding domain was divided into
its two structural lobes: I (aa 1–166) and II (aa 161–370).
The COOH-terminal peptide-binding domain was divided
into a b sandwich domain, III (aa 360–517), and an a helical
domain, IV (aa 510–625).
Six groups of three C57BL/6 mice were immunized with
120 pmol of OVA, OVA.TBhsp70, and OVA fused to seg-
ments I, II, III, and IV. CTL assays showed that splenocytes
from mice immunized with OVA.TBhsp70 and OVA fused
to segment II lysed T2-Kb cells in the presence, but not ab-
sence, of the OVA Kb epitope, SIINFEKL (Fig. 4). In con-
trast, cells from mice immunized with OVA and OVA fused
to segments I, III, and IV were ineffective, even at an E/T
ratio of 80:1. Levels of cytolysis obtained with splenocytes
from mice immunized with OVA.TBhsp70 and OVA fused
to segment II were indistinguishable (Fig. 4). These results
show that half of the ATP-binding domain of TBhsp70 (aa
161–370) is sufficient to stimulate substantial production of
anti-OVA CTL response in the absence of adjuvant.
Since it is highly unlikely that segment II retains chap-
erone activity, we conclude that the ability of the fusion
proteins to elicit CD81 T cells does not depend on the hsp
moieties’ chaperone properties. How then can one account
for the ability of these heat shock fusion proteins to act as
CD81 CTL immunogens? Our data would support a model
in which hsp70 bypasses the need for CD41 help by di-
rectly or indirectly activating or affecting the maturation
state of APCs, such as dendritic cells, in a manner similar to
some viruses (40). According to this model, hsp70 fusion
proteins may activate a few CD81 T cells to release immu-
nostimulatory cytokines in draining LNs. These cytokines
may, in turn, provide the help required to upregulate ex-
pression of costimulatory molecules on APCs in the LN,
Figure 1. OVA-specific CTLs elicited by immunization with
OVA.TBhsp70 fusion protein without adjuvant. The splenocytes from
mice immunized with OVA (n) or OVA.TBhsp70 (j) were incubated
with irradiated EG7-OVA cells for 6 d in the absence of added cytokines,
and then used as effector cells (E) in a standard 4-h cytotoxicity assay. The
51Cr-labeled target cells (T) were T2-Kb (dashed line) and T2-Kb pulsed
with SIINFEKL peptide (solid line) at 33 mg/ml. (A) Splenocytes from
wild-type C57BL/6 mice. (B) Splenocytes from CD42/2 mice. (C) Sple-
nocytes from b2m2/2 mice (this b2m2/2 experiment was not repeated).
Figure 2. Murine hsp70 fu-
sion protein elicits CTL re-
sponses in wild-type and CD42/2
mice. Soluble OVA.mhsp70 (d)
was injected without adjuvant
into C57BL/6 mice (A) and
CD42/2 mice (B).406 Hsp70 Fusion Proteins Elicit CD4-independent CTLs via Discrete Domain
leading to further CD81 T cell activation (40). Recent
studies demonstrate that exposure of macrophages to bacte-
rial and human hsp60 (41, 42), murine hsp70, and gp96 (3,
43) increases expression of adhesion molecules and cyto-
kines. We are currently examining expression of costimu-
latory molecules, adhesion molecules, and cytokines by
APCs after exposure to fusion proteins made with full-
length hsp70 or segment II.
Whatever the underlying mechanism, the ability of hsp70
fusion proteins to elicit CTL responses in the absence of
CD41 cells suggests that hsp70 may be a useful vehicle for
the development of prophylaxis and therapy of HIV-1 and
its opportunistic infections. Infection by HIV and its cousin
simian immunodeficiency virus (SIV) can lead to a substan-
tial reduction in CD41 T cells, thereby crippling the host’s
immune response to HIV and other pathogens. This loss of
CD41 cells is thought to impair the development and main-
tenance of CD81 CTL responses (44). Recent studies con-
clude that strong HIV-specific CTL responses are required
to keep HIV-1 infection in check and to destroy HIV-
infected cells (45–50). It will thus be of interest to deter-
mine whether hsp70 fusion constructs can elicit anti-SIV
CTL responses in SIV-infected macaques having low
CD41 T cell counts, and if similar effects are observed in
HIV-infected humans.
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